The Effectiveness of Cyclic Hydroxamic Acid CHA-5 against Drug-Resistant P388 Leukemia Strains.

Abstract

We studied the effectiveness of cyclic hydroxamic acid CHA-5 against drug-resistant and multidrug-resistant murine P388 leukemia strains. More than 60% mice receiving transplantation of rubomycin-resistant leukemia P388 strain survived after CHA-5 monotherapy; combined therapy with CHA-5 and cisplatin was also highly effective. Vincristine-resistant tumor was highly sensitive to combined treatment with CHA-5 and cyclophosphamide. It should be emphasized that standard antitumor agents were used in very low doses in combination therapy and CHA-5 significantly potentiated their effect.

• Authors: S A Goncharova, I V Vystorop, T A Raevskaya, N P Konovalova
• Journal: Bulletin of experimental biology and medicine (Bull Exp Biol Med) Vol. 163 Issue 3 Pg. 385-388 (Jul 2017) ISSN: 1573-8221 [Electronic] United States
• PMID: 28744633 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• Drug Combinations
• Hydroxamic Acids
• Vincristine
• Cyclophosphamide
• Cisplatin
• Daunorubicin

Topics

• Animals
• Antineoplastic Agents (chemical synthesis, pharmacology)
• Cisplatin (pharmacology)
• Cyclophosphamide (pharmacology)
• Daunorubicin (pharmacology)
• Drug Administration Schedule
• Drug Combinations
• Drug Resistance, Neoplasm (drug effects)
• Drug Synergism
• Hydroxamic Acids (chemical synthesis, pharmacology)
• Leukemia P388 (drug therapy, mortality, pathology)
• Mice
• Survival Analysis
• Vincristine (pharmacology)